Premium
Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril
Author(s) -
Elliott Henry L,
Macdonald Natalie J,
Meredith Peter A,
Reid John L
Publication year - 1992
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1992.20
Subject(s) - quinapril , pharmacokinetics , angiotensin converting enzyme , ace inhibitor , enzyme inhibitor , pharmacology , endocrinology , chemistry , medicine , dose–response relationship , enzyme , biochemistry , blood pressure
Single doses of the angiotensin converting enzyme (ACE) inhibitor quinapril were administered to salt replete normotensive men to investigate pharmacokinetics and dose responses. Maximal ACE inhibition was produced by the 2.5, 5, and 20 mg doses (but not by 0.5 mg), but there was evidence of dose‐dependency only for the duration of ACE inhibition. Quinaprilat was detectable in plasma up to 72 hours after all doses and the terminal phase half‐life was calculated at 26 ± 7 hours. Although there were dose‐related increases in area under the curve (AUC), the relationships between dose and both AUC and maximum concentration were nonlinear. These findings suggest that quinapril displays the same prolonged terminal phase half‐life that is characteristic of other ACE inhibitor drugs. The failure of doses above 2.5 mg to produce any further increase in the magnitude of ACE inhibition is consistent with an maximum effect dose‐response relationship, with the obvious implication that higher doses will increase only the duration not the magnitude of response. Clinical Pharmacology and Therapeutics (1992) 51, 260–265; doi: 10.1038/clpt.1992.20